TNFSF10 and neoplasm: The development of nanotechnology appears to be a promising strategy with several nano-based formulations of TRAIL and agonistic antibodies that help increase the circulating half-life and biodistribution of TRAIL in addition to its improved targeted delivery to tumor tissue.